ネオアンチゲンがんワクチン市場：ネオアンチゲンタイプ,治療標的,ワクチンプラットフォーム,投与経路,エンドユーザー別-2025-2030年世界予測

ネオアンチゲンがんワクチン市場は、2024年には3億7,866万米ドルとなり、2025年には4億3,455万米ドル、CAGR15.01%で成長し、2030年には8億7,678万米ドルに達すると予測されています。

ネオアンチゲンがんワクチンは、腫瘍特異的抗原を標的とする身体の免疫システムの潜在能力を活用することで、がんとの闘いにおける有望なアプローチとして台頭してきています。この革新的な治療戦略は、個々の患者に合わせた治療というコンセプトのもとに構築されており、それによって各腫瘍のユニークな変異プロファイルに対処します。この分野の進化は、ゲノム配列決定とバイオインフォマティクスの飛躍的進歩により、免疫反応を引き起こすネオアンチゲンをより正確に同定できるようになったことによる。その結果、臨床医や研究者は、これまで標準的な治療法を免れてきたがん細胞を認識し排除するよう免疫系を刺激するワクチンを設計できるようになってきています。

最近の進歩は、腫瘍免疫学に対する理解を深めただけでなく、標準的な腫瘍学プロトコルに個別化療法を組み込む道を開いた。全身毒性を軽減しながら患者の転帰を改善することが期待されるため、このアプローチは従来の治療法に代わる魅力的な選択肢となっています。さらに、科学界は個別化新抗原と共有新抗原への注力を強めており、これらのワクチンの変革的な可能性を強調しています。本エグゼクティブサマリーでは、現在の市場力学、革新的な技術シフト、セグメンテーションに関する洞察を詳細に概観し、ネオアンチゲンがんワクチン分野における今後のロードマップを明確に示します。

ネオアンチゲンワクチンの情勢を再定義する変革的シフト

新抗原がんワクチンの状況は、研究、技術、臨床応用における一連の変革的シフトに牽引され、大きな変化を遂げつつあります。初期の前臨床試験での成功は、現在では複数の臨床評価段階へと移行しており、科学的なブレークスルーを具体的な治療法へと結びつける世界の努力を反映しています。人工知能と高度なバイオインフォマティクス・ツールの統合により、潜在的な新抗原ターゲットの迅速な同定が可能となり、ワクチン開発の精度とスピードの両方が向上しました。これと並行して、進化する規制の枠組みは、個別化治療がもたらす特有の課題に適応し、より迅速かつ厳格な承認プロセスを促進しています。

同時に、学術機関、バイオテクノロジー企業、製薬企業間の連携が、共同研究を通じてイノベーションを加速させています。このような学際的なアプローチは、従来の治療パラダイムを再定義し、がんにおける免疫応答メカニズムのより総合的な理解につながっています。研究者が腫瘍の遺伝学と免疫回避の間の複雑な相互作用を解読するにつれ、ワクチンの有効性を高めるために標的とすることができる新規の経路も明らかになりつつあります。さらに、RNAからペプチドベースの様式まで、ワクチン・プラットフォームにおける技術的進歩は、治療の選択肢をさらに広げています。このような変革的なシフトは、治療成績の改善を約束するだけでなく、世界中のがん患者の多様なニーズに対応する態勢を整え、より適応性と弾力性のある市場エコシステムを推進します。

ネオアンチゲンがんワクチン市場のセグメンテーション洞察の深掘り

ネオアンチゲンがんワクチン市場の包括的な分析により、多次元にわたる強固なセグメンテーションに根ざした洞察が明らかになりました。ネオアンチゲンタイプの検討において、市場分析は個別化ネオアンチゲンと共有ネオアンチゲンを区別します。個別化ネオアンチゲンでは、免疫エスケープ変異と体細胞変異のニュアンスに焦点が当てられ、これらは有効性と患者特異的カスタマイズのための重要な指標となります。共有ネオアンチゲンの領域では、親和性ペプチドと一般的な腫瘍変異が注目され、異なる患者プロファイルで再発するだけでなく、ワクチンデザインに広く応用できる可能性を持つターゲットの価値が強調されています。

治療標的別にさらに細分化すると、免疫チェックポイント遮断を中心とする没入型戦略と腫瘍新抗原を標的とする戦略との分岐が強調されます。免疫チェックポイント経路は、CTLA-4阻害剤とPD-1阻害剤を中心とした解析でさらに細分化されています。腫瘍新抗原を変異型と非変異型に細分化することで、さらに詳細な解析が可能となり、潜在的なワクチン反応性についての洞察が得られます。セグメンテーションのもう一つの重要な層は、利用可能なワクチンプラットフォームの多様性に由来します。市場は、細胞ベースワクチン、DNAベースワクチン、ペプチドベースワクチン、RNAベースワクチンに区分されます。これらのカテゴリーの中で、細胞ベースのアプローチは樹状細胞ワクチンとT細胞ワクチンを掘り下げているのに対し、DNAプラットフォームは円形とプラスミドベースの両方の戦略を探求しています。同様に、ペプチドプラットフォームは長鎖ペプチドと合成ペプチドを扱い、RNAベースの技術は従来のmRNAワクチンと次世代RNAプラットフォームによってランク付けされます。また、皮内、静脈内、経口、皮下などの投与経路や、がん治療センター、病院、研究機関などのエンドユーザーについても調査しています。これらのセグメンテーションに関する洞察は、戦略的な市場投資や的を絞った研究イニシアチブの礎となるものです。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん疾患の罹患率の増加により、個別化がんワクチンソリューションの強力な調査が求められています。
    • 個別化がん治療と予防がん治療の利点に関する国民の意識向上
    • がん研究開発イニシアチブに対する政府の支援政策と資金提供
  • 抑制要因
    • ネオアンチゲンがんワクチンの重大な副作用に関する懸念
  • 機会
    • バイオテクノロジー企業間の戦略的連携により、新抗原ワクチン調査の進歩が加速
    • 革新的な技術の進歩により、新抗原がんワクチンの潜在的応用が促進される
  • 課題
    • 個別化ワクチンの承認のための厳格な規制環境とコンプライアンス
• 市場セグメンテーション分析
  • ネオアンチゲンタイプ：個人の腫瘍に特有の変異を標的とする個別化ネオアンチゲンがんワクチンの必要性が高まっている
  • エンドユーザー：個別化治療の有効性向上のため、がん治療センターによるネオアンチゲンワクチンの利用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 ネオアンチゲンがんワクチン市場ネオアンチゲンタイプ別

• パーソナライズされたネオアンチゲン
  • 免疫逃避変異
  • 体細胞変異
• 共有された新抗原
  • 親和性ペプチド
  • 一般的な腫瘍変異

第7章 ネオアンチゲンがんワクチン市場セラピューティックターゲット

• 免疫チェックポイント阻害
  • CTLA-4阻害剤
  • PD-1阻害剤
• 腫瘍新抗原
  • 変異したネオアンチゲン
  • 変異していないネオアンチゲン

第8章 ネオアンチゲンがんワクチン市場ワクチンプラットフォーム

• 細胞ベースのワクチン
  • 樹状細胞ワクチン
  • T細胞ワクチン
• DNAベースのワクチン
  • 環状DNAプラットフォーム
  • プラスミドDNAワクチン
• ペプチドベースのワクチン
  • 長鎖ペプチド
  • 合成ペプチド
• RNAベースのワクチン
  • mRNAワクチン
  • 次世代RNAプラットフォーム

第9章 ネオアンチゲンがんワクチン市場投与経路別

• 皮内
• 静脈内
• オーラル
• 皮下

第10章 ネオアンチゲンがんワクチン市場：エンドユーザー別

• がん治療センター
• 病院
• 調査機関

第11章 南北アメリカのネオアンチゲンがんワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のネオアンチゲンがんワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのネオアンチゲンがんワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Agenus Inc.
• AstraZeneca PLC
• Avidea Technologies
• Ayala Pharmaceuticals, Inc.
• BioLineRx Ltd.
• BioNTech SE
• BioVaxys Technology Corp.
• Brightpath Biotherapeutics Co., Ltd.
• CureVac N.V.
• Elicio Therapeutics Inc
• F. Hoffmann-La Roche Ltd.
• Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
• Genocea Biosciences Inc
• GenScript Biotech Corporation
• Gilead Sciences, Inc.
• Gritstone bio, Inc.
• Immunomic Therapeutics, Inc.
• ISA Pharmaceuticals B.V.
• Medigene AG
• Merck & Co., Inc.
• Moderna, Inc.
• Neophore Limited
• Nouscom AG
• Nykode Therapeutics ASA
• OSE Immunotherapeutics
• Takis S.r.l.

LIST OF FIGURES

• FIGURE 1. NEOANTIGEN CANCER VACCINE MARKET MULTI-CURRENCY
• FIGURE 2. NEOANTIGEN CANCER VACCINE MARKET MULTI-LANGUAGE
• FIGURE 3. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
• FIGURE 4. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEOANTIGEN CANCER VACCINE MARKET DYNAMICS
• TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 76. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 77. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 84. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 85. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 86. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 87. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 88. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 89. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 90. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 92. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 93. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 94. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 95. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 96. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 97. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 98. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 99. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 100. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 101. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 102. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 103. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 105. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 106. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 107. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 108. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 109. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 110. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 111. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 112. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 113. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 114. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 115. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 116. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 118. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 119. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 120. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 121. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 122. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 123. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 124. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 125. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 126. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 127. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 128. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 129. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 133. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 134. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 135. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 136. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 137. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 138. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 139. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 140. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 142. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 145. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 146. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 147. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 148. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 149. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 150. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 151. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 152. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 153. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 154. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 155. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 156. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 157. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 159. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 160. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 161. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 162. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 163. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 164. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 165. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 166. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 167. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 168. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 169. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 170. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 172. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 173. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 174. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 175. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 176. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 177. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 178. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 179. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 180. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 181. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 182. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 183. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 184. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 185. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 186. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 187. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 188. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 189. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 190. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 191. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 192. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 193. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 194. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 195. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 196. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 198. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 199. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 200. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 201. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 202. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 203. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 204. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 205. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 206. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 207. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 208. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 209. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 211. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 212. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 213. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 214. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 215. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 216. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 217. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 218. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 219. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 220. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 221. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 222. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 223. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 224. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 225. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 226. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 227. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 228. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 229. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 230. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 231. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 232. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 233. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 234. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 235. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 237. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 238. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 239. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 240. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 241. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 242. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 243. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 244. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 245. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 246. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 247. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 248. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 252. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 254. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 256. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 258. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 260. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 262. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 263. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 264. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 265. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 266. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 267. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 268. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 269. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 270. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 271. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 272. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 273. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 274. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 275. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 276. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 277. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 278. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 279. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 280. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 281. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 282. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 283. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 284. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 285. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 286. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 287. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 288. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 289. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 290. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 291. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 292. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 293. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 294. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 295. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 296. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 297. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 298. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
• TABLE 299. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
• TABLE 300. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA NE

The Neoantigen Cancer Vaccine Market was valued at USD 378.66 million in 2024 and is projected to grow to USD 434.55 million in 2025, with a CAGR of 15.01%, reaching USD 876.78 million by 2030.

Neoantigen cancer vaccines are emerging as a promising approach in the fight against cancer by harnessing the potential of the body's immune system to target tumor-specific antigens. This innovative therapeutic strategy is built around the concept of tailoring treatments to individual patients, thereby addressing the unique mutational profile of each tumor. The evolution of this field has been driven by breakthroughs in genomic sequencing and bioinformatics, enabling a more precise identification of neoantigens that can provoke an immune response. As a result, clinicians and researchers are increasingly able to design vaccines that stimulate the immune system to recognize and eliminate cancer cells, which have previously evaded standard treatment methods.

Recent advancements have not only enhanced our understanding of tumor immunology but have also paved the way for integrating personalized therapies into standard oncology protocols. The promise of improving patient outcomes while mitigating systemic toxicity makes this approach an attractive alternative to conventional treatments. Moreover, the scientific community's intensified focus on both personalized and shared neoantigens has underscored the transformative potential of these vaccines. This executive summary provides a detailed overview of current market dynamics, transformative technological shifts, and segmentation insights, building a clear picture of the roadmap ahead in the neoantigen cancer vaccine arena.

Transformative Shifts Redefining the Neoantigen Vaccine Landscape

The landscape of neoantigen cancer vaccines is undergoing profound change, driven by a series of transformative shifts in research, technology, and clinical application. Early preclinical success has now transitioned into multiple stages of clinical evaluation, reflecting a concerted global effort to translate scientific breakthroughs into tangible therapies. The integration of artificial intelligence and advanced bioinformatics tools has enabled a more rapid identification of potential neoantigen targets, enhancing both the precision and speed of vaccine development. In parallel, evolving regulatory frameworks are adapting to the unique challenges posed by personalized treatments, thereby facilitating faster, yet rigorous, approval processes.

Simultaneously, partnerships among academic institutions, biotech firms, and pharmaceutical companies have accelerated innovation through collaborative research efforts. This multidisciplinary approach is redefining traditional treatment paradigms, leading to a more holistic understanding of immune response mechanisms in cancer. As researchers decipher the complex interplay between tumor genetics and immune evasion, they are also uncovering novel pathways that can be targeted to enhance the efficacy of vaccines. Additionally, technological advancements in vaccine platforms, ranging from RNA to peptide-based modalities, are further expanding treatment options. These transformative shifts not only promise improved outcomes but also drive a more adaptable and resilient market ecosystem that is poised to address the diverse needs of oncology patients worldwide.

Deep Dive Into Segmentation Insights for the Neoantigen Cancer Vaccine Market

A comprehensive analysis of the neoantigen cancer vaccine market reveals insights that are rooted in robust segmentation across multiple dimensions. In examining the neoantigen type, the market analysis distinguishes between personalized neoantigens and shared neoantigens. For personalized neoantigens, the focus intensifies on the nuances of immune escape mutations versus somatic mutations, which provide critical benchmarks for efficacy and patient-specific customization. In the realm of shared neoantigens, attention is directed to affinity peptides and common tumor mutations, emphasizing the value of targets that are not only recurrent across different patient profiles but also hold potential for broad applicability in vaccine design.

Further segmentation by therapeutic target underscores a bifurcation between immersive strategies centered on immune checkpoint blockade and those targeting tumor neoantigens. The immune checkpoint pathway is further refined with analyses centered on CTLA-4 and PD-1 inhibitors. The subdivision of tumor neoantigens into mutated versus non-mutated variants offers additional granularity, affording insights into potential vaccine responsiveness. Another important layer of segmentation is derived from the diversity of the vaccine platforms available. The market is segmented into cell-based vaccines, DNA-based vaccines, peptide-based vaccines, and RNA-based vaccines. Within these categories, cell-based approaches delve into dendritic cell vaccines and T-cell vaccines, whereas DNA platforms explore both circular and plasmid-based strategies. Likewise, peptide platforms address long and synthetic peptides, and RNA-based technologies are ranked by traditional mRNA vaccines alongside next-generation RNA platforms. Consideration is also given to the route of administration-spanning intradermal, intravenous, oral, and subcutaneous methods-and the end user, which includes cancer treatment centers, hospitals, and research institutes. These segmentation insights collectively form the cornerstone for strategic market investments and targeted research initiatives.

Based on Neoantigen Type, market is studied across Personalized Neoantigens and Shared Neoantigens. The Personalized Neoantigens is further studied across Immune Escape Mutations and Somatic Mutations. The Shared Neoantigens is further studied across Affinity Peptides and Common Tumor Mutations.

Based on Therapeutic Target, market is studied across Immune Checkpoint Blockade and Tumor Neoantigens. The Immune Checkpoint Blockade is further studied across CTLA-4 Inhibitors and PD-1 Inhibitors. The Tumor Neoantigens is further studied across Mutated Neoantigens and Non-Mutated Neoantigens.

Based on Vaccine Platform, market is studied across Cell-Based Vaccines, DNA-Based Vaccines, Peptide-Based Vaccines, and RNA-Based Vaccines. The Cell-Based Vaccines is further studied across Dendritic Cell Vaccines and T-Cell Vaccines. The DNA-Based Vaccines is further studied across Circular DNA Platforms and Plasmid DNA Vaccines. The Peptide-Based Vaccines is further studied across Long Peptides and Synthetic Peptides. The RNA-Based Vaccines is further studied across mRNA Vaccines and Next-Gen RNA Platforms.

Based on Administration Route, market is studied across Intradermal, Intravenous, Oral, and Subcutaneous.

Based on End User, market is studied across Cancer Treatment Centers, Hospitals, and Research Institutes.

Key Regional Insights Highlighting Global Market Variations

A regional analysis reveals distinct trends and growth potentials across key global markets. In the Americas, robust research infrastructures and established pharmaceutical markets have accelerated the clinical adoption of neoantigen vaccines. This region benefits from extensive clinical trials and significant investments in biotechnology, fostering an environment where personalized treatments are rapidly integrated into treatment protocols.

In Europe, the evolution of stringent yet adaptive regulatory frameworks, combined with a focus on precision medicine, is driving the uptake of innovative vaccine therapies. Markets in the Middle East and Africa, though emerging, are beginning to carve out niches as partnerships with international research bodies encourage technology transfer and skill development. Meanwhile, the Asia-Pacific region is experiencing a surge in market activity attributed to rapid economic growth and increased healthcare spending. The diverse regulatory landscapes and the high prevalence of cancer cases in this region underscore the strategic importance of harnessing advanced vaccine platforms and localized manufacturing capabilities. These regional insights illustrate not only varying levels of technological readiness and market maturity but also reveal opportunities for expanding the reach of neoantigen cancer vaccines into new and promising territories.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Analysis of Key Market Players Driving Innovation in Neoantigen Vaccines

The competitive landscape within the neoantigen cancer vaccine market is marked by the active involvement of several leading organizations that are driving innovation and market growth. Prominent firms such as Agenus Inc., AstraZeneca PLC, and Avidea Technologies are at the forefront of developing next-generation immunotherapies through robust research and development initiatives. Several other companies, including Ayala Pharmaceuticals, Inc. and BioLineRx Ltd., are also making significant strides by exploring novel vaccine formulations that offer improved immunogenic profiles. The rise of BioNTech SE and BioVaxys Technology Corp. as key innovators reflects the industry's shift towards rapidly scalable vaccination platforms coupled with high precision targeting.

Additional contributions from Brightpath Biotherapeutics Co., Ltd., CureVac N.V., and Elicio Therapeutics Inc. illustrate a diversified approach to vaccine development, balancing both traditional and cutting-edge delivery systems. F. Hoffmann-La Roche Ltd. and Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc. further amplify market innovation by leveraging their expansive global networks and multidisciplinary research teams. Emerging companies like Genocea Biosciences Inc. and GenScript Biotech Corporation are challenging long-held treatment paradigms with breakthrough research, while established firms such as Gilead Sciences, Inc. and Merck & Co., Inc. continue to expand their portfolios with strategic investments. The presence of Gritstone bio, Inc., Immunomic Therapeutics, Inc., and ISA Pharmaceuticals B.V. underscores the competitive dynamism in this sector, paralleled by Medigene AG, Moderna, Inc., and Neophore Limited stepping in to address diversified market needs. Companies such as Nouscom AG, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis S.r.l. bring specialized skills and insights that help to balance market offerings, ensuring that innovations are both scientifically robust and clinically impactful. This broad spectrum of players is collectively advancing the field while contributing to a vibrant, competitive environment.

The report delves into recent significant developments in the Neoantigen Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include Agenus Inc., AstraZeneca PLC, Avidea Technologies, Ayala Pharmaceuticals, Inc., BioLineRx Ltd., BioNTech SE, BioVaxys Technology Corp., Brightpath Biotherapeutics Co., Ltd., CureVac N.V., Elicio Therapeutics Inc, F. Hoffmann-La Roche Ltd., Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc., Genocea Biosciences Inc, GenScript Biotech Corporation, Gilead Sciences, Inc., Gritstone bio, Inc., Immunomic Therapeutics, Inc., ISA Pharmaceuticals B.V., Medigene AG, Merck & Co., Inc., Moderna, Inc., Neophore Limited, Nouscom AG, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis S.r.l.. Strategic Recommendations for Capitalizing on Neoantigen Vaccine Opportunities

Industry leaders are encouraged to adopt a multifaceted strategy that emphasizes both innovation and collaboration. Investment in cutting-edge research and the integration of advanced bioinformatics tools are critical to stay ahead in vaccine development. Embracing modular vaccine platforms that allow rapid customization and scalability will enable stakeholders to better address the variability in tumor profiles and patient-specific needs. Strategic partnerships with academic institutions and research laboratories can further accelerate the pace of discovery, while clinical collaborations will help validate promising approaches in real-world settings. Additionally, streamlining regulatory pathways and investing in robust clinical trial designs will serve to reduce time-to-market, ensuring that breakthrough therapies reach patients without unnecessary delays. The convergence of these strategies will not only foster growth but also cement a competitive edge in the dynamic field of neoantigen cancer vaccines.

Conclusion: Charting the Future of Personalized Cancer Immunotherapy

In conclusion, the neoantigen cancer vaccine market stands at a pivotal juncture, driven by innovative scientific breakthroughs and evolving clinical technologies. The integration of personalized therapies, supported by meticulous segmentation across neoantigen types, therapeutic targets, and vaccine platforms, positions the field for transformative change. Global regional dynamics further amplify market opportunities, while a robust competitive landscape ensures continuous innovation through strategic R&D investments. As the sector advances, stakeholders will increasingly rely on data-driven insights and collaborative approaches to address complex oncological challenges. This comprehensive market review underscores the immense potential of neoantigen vaccines to reshape cancer treatment paradigms and offers a roadmap for achieving sustainable growth and improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of cancer diseases compelling robust research in personalized cancer vaccine solutions
    • 5.1.1.2. Increasing public awareness about the benefits of personalized and preventive cancer treatments
    • 5.1.1.3. Supportive government policies and funding for cancer research and development initiatives
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with significant side effects of neoantigen cancer vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Strategic collaborations among biotech companies accelerating advancements in neoantigen vaccine research
    • 5.1.3.2. Innovative technological advancements boosting the potential applications of neoantigen cancer vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory environments and compliance for personalized vaccine approval
• 5.2. Market Segmentation Analysis
  • 5.2.1. Neoantigen Type: Increasing need for personalized neoantigen cancer vaccines to target unique mutations specific to an individual's tumor
  • 5.2.2. End User: Expanding utilization of neoantigen vaccines by cancer treatment centers for personalized treatment efficacy
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neoantigen Cancer Vaccine Market, by Neoantigen Type

• 6.1. Introduction
• 6.2. Personalized Neoantigens
  • 6.2.1. Immune Escape Mutations
  • 6.2.2. Somatic Mutations
• 6.3. Shared Neoantigens
  • 6.3.1. Affinity Peptides
  • 6.3.2. Common Tumor Mutations

7. Neoantigen Cancer Vaccine Market, by Therapeutic Target

• 7.1. Introduction
• 7.2. Immune Checkpoint Blockade
  • 7.2.1. CTLA-4 Inhibitors
  • 7.2.2. PD-1 Inhibitors
• 7.3. Tumor Neoantigens
  • 7.3.1. Mutated Neoantigens
  • 7.3.2. Non-Mutated Neoantigens

8. Neoantigen Cancer Vaccine Market, by Vaccine Platform

• 8.1. Introduction
• 8.2. Cell-Based Vaccines
  • 8.2.1. Dendritic Cell Vaccines
  • 8.2.2. T-Cell Vaccines
• 8.3. DNA-Based Vaccines
  • 8.3.1. Circular DNA Platforms
  • 8.3.2. Plasmid DNA Vaccines
• 8.4. Peptide-Based Vaccines
  • 8.4.1. Long Peptides
  • 8.4.2. Synthetic Peptides
• 8.5. RNA-Based Vaccines
  • 8.5.1. mRNA Vaccines
  • 8.5.2. Next-Gen RNA Platforms

9. Neoantigen Cancer Vaccine Market, by Administration Route

• 9.1. Introduction
• 9.2. Intradermal
• 9.3. Intravenous
• 9.4. Oral
• 9.5. Subcutaneous

10. Neoantigen Cancer Vaccine Market, by End User

• 10.1. Introduction
• 10.2. Cancer Treatment Centers
• 10.3. Hospitals
• 10.4. Research Institutes

11. Americas Neoantigen Cancer Vaccine Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Neoantigen Cancer Vaccine Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Everest Medicines Initiated personalized mRNA cancer vaccines with EVM16 clinical trial for neoantigen targeting
  • 14.3.2. Achilles Therapeutics and Arcturus Therapeutics to collaborate on next-generation personalized mRNA cancer vaccine research
  • 14.3.3. Transgene and NEC expand collaboration to advance TG4050 neoantigen cancer vaccine into Phase I/II trial
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agenus Inc.
• 2. AstraZeneca PLC
• 3. Avidea Technologies
• 4. Ayala Pharmaceuticals, Inc.
• 5. BioLineRx Ltd.
• 6. BioNTech SE
• 7. BioVaxys Technology Corp.
• 8. Brightpath Biotherapeutics Co., Ltd.
• 9. CureVac N.V.
• 10. Elicio Therapeutics Inc
• 11. F. Hoffmann-La Roche Ltd.
• 12. Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
• 13. Genocea Biosciences Inc
• 14. GenScript Biotech Corporation
• 15. Gilead Sciences, Inc.
• 16. Gritstone bio, Inc.
• 17. Immunomic Therapeutics, Inc.
• 18. ISA Pharmaceuticals B.V.
• 19. Medigene AG
• 20. Merck & Co., Inc.
• 21. Moderna, Inc.
• 22. Neophore Limited
• 23. Nouscom AG
• 24. Nykode Therapeutics ASA
• 25. OSE Immunotherapeutics
• 26. Takis S.r.l.